Concord Biotech Intrinsic Value
CONCORDBIO Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹530.64 | ₹424.51 - ₹636.77 | -55.8% | EPS: ₹24.12, Sector P/E: 22x |
| Book Value Method | asset | ₹3002.25 | ₹2702.03 - ₹3302.48 | +150.0% | Book Value/Share: ₹1648.18, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1912.73 | ₹1721.46 - ₹2104.00 | +59.3% | Revenue/Share: ₹956.36, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2401.80 | ₹2161.62 - ₹2641.98 | +100.0% | EBITDA: ₹416.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2512.59 | ₹2010.07 - ₹3015.11 | +109.2% | CF Growth: 10.1%, Discount: 15% |
| PEG Ratio Method | growth | ₹360.27 | ₹324.24 - ₹396.30 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹372.65 | ₹335.38 - ₹409.92 | -69.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹2401.80 | ₹2161.62 - ₹2641.98 | +100.0% | ROE: 13.9%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹945.76 | ₹851.18 - ₹1040.34 | -21.2% | EPS: ₹24.12, BVPS: ₹1648.18 |
Want to compare with current market value? Check CONCORDBIO share price latest .
Valuation Comparison Chart
CONCORDBIO Intrinsic Value Analysis
What is the intrinsic value of CONCORDBIO?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Concord Biotech (CONCORDBIO) is ₹1912.73 (median value). With the current market price of ₹1200.90, this represents a +59.3% variance from our estimated fair value.
The valuation range spans from ₹360.27 to ₹3002.25, indicating ₹360.27 - ₹3002.25.
Is CONCORDBIO undervalued or overvalued?
Based on our multi-method analysis, Concord Biotech (CONCORDBIO) appears to be trading below calculated value by approximately 59.3%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 29.87 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 13.9% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 36.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.52x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Concord Biotech
Additional stock information and data for CONCORDBIO
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹245 Cr | ₹165 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹266 Cr | ₹189 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹246 Cr | ₹167 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹208 Cr | ₹152 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹167 Cr | ₹70 Cr | Positive Free Cash Flow | 7/10 |